Early Medical Technology Assessments of Medical Devices and Tests

• Autorzy: Boglárka Mikudina , Ken Redekop
• Języki publikacji: EN

Abstrakty

EN

Background: Classic medical technology assessment (MTA) is typically conducted at the end of the development process to assess the overall value of a drug, medical device or diagnostic test. Recently, researchers and manufacturers have recognized that MTA in the early phases could help to make better decisions about further development, the regulatory and reimbursement strategy, and allocating public support for new technologies. The aim of this study is to introduce the most commonly used methods in early MTAs of emerging technologies and examine which methods have been used in the early MTAs of medical devices and tests. Methods: An explorative literature review. Results: Classic MTA supports particularly regulators and payers in market and reimbursement decisions, while early MTA primarily supports decisions of manufacturers about investments and strategies regarding further development as well as decisions by policymakers about public support. Important methods that can be used in early MTAs of medical devices include early health economic modelling, the headroom method, the Bayesian analytical framework, clinical trial simulation, multi-criteria decision analysis and value of information analysis. Only a few articles have been described early HTAs of devices and tests and most of these have used economic modelling, sometimes in combination with other methods. Conclusions: Various methods can be applied in performing early MTA. While early MTA follows the same steps as classic MTA, repeated assessments and sensitivity analysis play a more significant role.(original abstract)

Słowa kluczowe

EN

Medical technology; Medicine; Diagnostic test; Medical device

PL

Technologia medyczna; Medycyna; Badanie diagnostyczne; Wyroby medyczne

• Czasopismo: Journal of Health Policy and Outcomes Research
• Rocznik: 2013
• Numer: nr 1
• Strony: 26--37

Twórcy

autor

Boglárka Mikudina

• Erasmus University,The Netherlands

autor

Ken Redekop

• Erasmus University, Rotterdam, The Netherlands

Bibliografia

• Pietzsch JB., Pate-Cornell ME.: Early technology assessment of new medical devices. Int J Technol Assess Health Care 2008 Winter; 24(1): 36-44
• Douw K., Vondeling H., Eskildsen D., Simpson S.: Use of the Internet in scanning the horizon for new and emerging health technologies: a survey of agencies involved in horizon scanning. J Med Internet Res 2003 Jan-Mar; 5(1): e6
• Hartz S., John J.: Public health policy decisions on medical innovations: what role can early economic evaluation play? Health Policy 2009 Feb; 89(2): 184-192
• Hartz S., John J.: Contribution of economic evaluation to decision making in early phases of product development: a methodological and empirical review. Int J Technol Assess Health Care 2008 Fall; 24(4): 465-472
• Drummond MF., O'Brien B., Stoddart GL., Torrance GW. Methods for the economic evaluation of health care programmes. 2nd edit. Oxford (UK), Oxford University Press 1997
• McAteer H., Lilford R. Investing in Medical Technologies: The Headroom Method [monograph on the internet]. Birmingham:College of Medicine and Dentistry, School of Health and Population Sciences, Public Health, Epidemiology and Biostatistics, University of Birmingham 2009; Available from: http://www.haps.bham.ac.uk/publichealth/methodology/hes/Headroom_brochure.pdf; [Accessed: 2011 March 3]
• IJzerman MJ., Steuten LM.: Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl Health Econ Health Policy, 2011; 9(5): 331-47
• Vallejo-Torres L., Steuten LM., Buxton MJ., Girling AJ., Lilford RJ., Young T.: Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach. Int J Technol Assess Health Care, 2008 Fall; 24(4): 459-464
• Health Council of the Netherlands. Value for our money. Deciding on publicinvestments in health research [mongraph on the internet] The Hague: Health Council of the Netherlands; publication no. 2010/16. Available from: http://www.gezondheidsraad.nl/sites/default/files/201016.pdf; [Accessed: 2011 Apr 4]
• Guston D., Sarewitz D.: Real-time technology assessment. Technology in Society, 2002 -01-01; 24(1-2): 93-109
• Wild C., Langer T.: Emerging health technologies: informing and supporting health policy early. Health Policy, 2008 Aug; 87(2): 160-171
• Trikalinos TA., Siebert U., Lau J.: Decision-analytic modeling to evaluate benefits and harms of medical tests: uses and limitations. Med Decis Making, 2009 Sep-Oct; 29(5): E22-9
• Annemans L., Geneste B., Jolain B.: Early modelling for assessing health and economic outcomes of drug therapy. Value Health, 2000 Nov-Dec; 3(6): 427-434
• Gaultney JG., Sanhueza E., Janssen JJ., Redekop WK., Uyl-de Groot CA.: Application of cost-effectiveness analysis to demonstrate the potential value of companion diagnostics in chronic myeloid leukemia. Pharmacogenomics, 2011 Mar; 12(3): 411-421
• O'Prinsen AC., Gaultney JG., Redekop WK. Universal Steps for Conducting Early-Stage Medical Technology Assessment. ISPOR Connections 2009; 15(6): 4-6
• Spiegelhalter DJ., Myles JP., Jones DR., Abrams KR.: Methods in health service research. An introduction to Bayesian methods in health technology assessment. Br Med J, 1999 Aug 21; 319(7208): 508-512
• Spiegelhalter DJ., Myles JP., Jones DR., Abrams KR.: Bayesian methods in health technology assessment: a review. Health Technol Assess, 2000; 4(38): 1-130
• Miller P.: Role of Pharmacoeconomic Analysis in R&D Decision Making: When, Where, How? Pharmacoeconomics, 2005 01; 23(1): 1-12
• Hughes DA., Walley T.: Economic evaluations during early (phase II) drug development: a role for clinical trial simulations? Pharmacoeconomics, 2001; 19(11): 1069-1077.
• Girard P.: Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol, 2005 Mar; 96(3): 228-234
• Abbas I., Rovira J., Casanovas J. Clinical trial optimization: Monte Carlo simulation Markov model for planning clinical trials recruitment. Contemp Clin Trials, 2007 May; 28(3): 220-231
• Holford NHG., Kimko HC., Monteleone JPR., Peck CC.: Simulation of clinical trials. Annu Rev Pharmacol Toxicol, 2000; 40: 209-234
• Saaty TL.: Highlights and critical points in the theory and application of the Analytic Hierarchy Process. Eur J Oper Res, 1994 5/5; 74(3): 426-447
• Hummel M., Steuten L., Groothuis-Oudshoorn K., IJzerman M. Using the analytic hierarchy process to filling missing gaps in early health economic modeling. Meeting of the Lowlands Health Economics Study Group 2011; The Netherlands, 2011
• Briggs A., Sculpher M.: An Introduction to Markov Modelling for Economic Evaluation. Pharmacoeconomics, 1998 04; 13(4): 397-409
• Dong H., Coyle D., Buxton M.: Value of information analysis for a new technology: computer-assisted total knee replacement. Int J Technol Assess Health Care, 2007 Summer; 23(3): 337-342
• Boyd KA., Fenwick E., Briggs A.: Using an iterative approach to economic evaluation in the drug development process. Drug Dev Res 2010; 71(8): 470-477
• Claxton K., Ginnelly L., Sculpher M., Philips Z., Palmer S.: A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. Health Technol Assess, 2004 Jul; 8(31): 1-103, iii
• Dong H., Buxton M. Early assessment of the likely cost-effectiveness of a new technology: A Markov model with probabilistic sensitivity analysis of computer-assisted total knee replacement. Int J Technol Assess Health Care, 2006 Spring; 22(2): 191-202
• McAteer H., Cosh E., Freeman G., Pandit A., Wood P., Lilford R.: Cost-effectiveness analysis at the development phase of a potential health technology: examples based on tissue engineering of bladder and urethra. J Tissue Eng Regen Med, 2007 Sep-Oct; 1(5): 343-349
• Postmus D., de Graaf G., Hillege HL., Steyerberg EW., Buskens E.: A method for the early health technology assessment of novel biomarker measurement in primary prevention programs. Stat Med, 2012 Oct 15; 31(23): 2733-44
• Chicoye A., Wilson G., Griffin A., Goeau-Brissoniere PO. How should HTA methods be adapted to meet the rising expectations of decision makers for medical devices and diagnostics reimbursement?. Presented at the ISPOR 12th Annual European Congress. Athens, 2009. http://www.ispor.org/sigs/HTA_MD/12thEuroIP_Medica%20Device.pdf; [Accessed: 06 June 2011]
• Bossuyt PMM. Evidence-based Medical Testing. Report prepared for theDutch Health Care Insurance Board [monograph on the internet] Amsterdam: Dutch Health Care Insurance Board. Available from: http://www.cvz.nl/binaries/content/documents/cvzinternet/nl/documenten/rapporten/2011/rpt1101-medische-tests.pdf; [Accessed: 2011 June 30]
• Fineberg HV.: Evaluation of computed tomography: achievement and challenge. AJR Am J Roentgenol, 1978 Jul; 131(1): 1-4
• Holmstrom S., Chicoye A., Xie F., Garfield S. Moving forward with HTA for medical devices and diagnostic products! The ISPOR global health care systems road map. Presented at the ISPOR 15th International Meeting. Atlanta, Georgia, 2010. Available from: http://www.ispor.org/meetings/atlanta0510/documents/Forum2010AllHTA.pdf; [Accessed: 06 June 2011]
• Akekurst R., Landa K. Considerations for technology assessment of diagnostic products. Presented at the ISPOR 13th Annual European Congress, Prague 2010. Available from: http://www.ispor.org/sigs/HTA_MD/MDDWorkshop19Prague2010.pdf; [Accessed: 06 June 2011]
• Siebert M., Clauss LC., Carlisle M., Casteels B., de Jong P., Kreuzer M. et al. Health technology assessment for medical devices in Europe. What must be considered. Int J Technol Assess Health Care, 2002 Summer; 18(3): 733-740

Identyfikatory

DOI

10.7365/JHPOR.2013.3.2